Primary care use of FRAX®: Absolute fracture risk assessment in postmenopausal women and older men

Ethel S. Siris, Sanford Baim, Aurelia Nattiv

Research output: Contribution to journalArticle

49 Citations (Scopus)

Abstract

Osteoporosis-related fractures (low-trauma or fragility fractures) cause substantial disability, health care costs, and mortality among postmenopausal women and older men. Epidemiologic studies indicate that at least half the population burden of osteoporosis-related fractures affects persons with osteopenia (low bone density), who comprise a larger segment of the population than those with osteoporosis. The public health burden of fractures will fail to decrease unless the subset of patients with low bone density who are at increased risk for fracture are identified and treated. Risk stratification for medically appropriate and cost-effective treatment is facilitated by the World Health Organization (WHO) FRAX® algorithm, which uses clinical risk factors, bone mineral density, and country-specific fracture and mortality data to quantify a patient's 10-year probability of a hip or major osteoporotic fracture. Included risk factors comprise femoral neck bone mineral density, prior fractures, parental hip fracture history, age, gender, body mass index, ethnicity, smoking, alcohol use, glucocorticoid use, rheumatoid arthritis, and secondary osteoporosis. FRAX® was developed by the WHO to be applicable to both postmenopausal women and men aged 40 to 90 years; the National Osteoporosis Foundation Clinician's Guide focuses on its utility in postmenopausal women and men aged > 50 years. It is validated to be used in untreated patients only. The current National Osteoporosis Foundation Guide recommends treating patients with FRAXR® 10-year risk scores of ≥ 3% for hip fracture or ≥ 20% for major osteoporotic fracture, to reduce their fracture risk. Additional risk factors such as frequent falls, not represented in FRAX®, warrant individual clinical judgment. FRAX® has the potential to demystify fracture risk assessment in primary care for patients with low bone density, directing clinical fracture prevention strategies to those who can benefit most.

Original languageEnglish
Pages (from-to)82-90
Number of pages9
JournalPostgraduate Medicine
Volume122
Issue number1
DOIs
StatePublished - Jan 1 2010

Fingerprint

Osteoporosis
Primary Health Care
Bone Density
Osteoporotic Fractures
Hip Fractures
Health Care Costs
Mortality
Metabolic Bone Diseases
Femur Neck
Glucocorticoids
Population
Hip
Epidemiologic Studies
Rheumatoid Arthritis
Body Mass Index
Public Health
Smoking
Alcohols
Wounds and Injuries

Keywords

  • Clinical risk factors
  • Fracture
  • FRAX®
  • Osteopenia
  • Osteoporosis

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Primary care use of FRAX® : Absolute fracture risk assessment in postmenopausal women and older men. / Siris, Ethel S.; Baim, Sanford; Nattiv, Aurelia.

In: Postgraduate Medicine, Vol. 122, No. 1, 01.01.2010, p. 82-90.

Research output: Contribution to journalArticle

Siris, Ethel S. ; Baim, Sanford ; Nattiv, Aurelia. / Primary care use of FRAX® : Absolute fracture risk assessment in postmenopausal women and older men. In: Postgraduate Medicine. 2010 ; Vol. 122, No. 1. pp. 82-90.
@article{927362109fc24ee5a9382d540723b87e,
title = "Primary care use of FRAX{\circledR}: Absolute fracture risk assessment in postmenopausal women and older men",
abstract = "Osteoporosis-related fractures (low-trauma or fragility fractures) cause substantial disability, health care costs, and mortality among postmenopausal women and older men. Epidemiologic studies indicate that at least half the population burden of osteoporosis-related fractures affects persons with osteopenia (low bone density), who comprise a larger segment of the population than those with osteoporosis. The public health burden of fractures will fail to decrease unless the subset of patients with low bone density who are at increased risk for fracture are identified and treated. Risk stratification for medically appropriate and cost-effective treatment is facilitated by the World Health Organization (WHO) FRAX{\circledR} algorithm, which uses clinical risk factors, bone mineral density, and country-specific fracture and mortality data to quantify a patient's 10-year probability of a hip or major osteoporotic fracture. Included risk factors comprise femoral neck bone mineral density, prior fractures, parental hip fracture history, age, gender, body mass index, ethnicity, smoking, alcohol use, glucocorticoid use, rheumatoid arthritis, and secondary osteoporosis. FRAX{\circledR} was developed by the WHO to be applicable to both postmenopausal women and men aged 40 to 90 years; the National Osteoporosis Foundation Clinician's Guide focuses on its utility in postmenopausal women and men aged > 50 years. It is validated to be used in untreated patients only. The current National Osteoporosis Foundation Guide recommends treating patients with FRAXR{\circledR} 10-year risk scores of ≥ 3{\%} for hip fracture or ≥ 20{\%} for major osteoporotic fracture, to reduce their fracture risk. Additional risk factors such as frequent falls, not represented in FRAX{\circledR}, warrant individual clinical judgment. FRAX{\circledR} has the potential to demystify fracture risk assessment in primary care for patients with low bone density, directing clinical fracture prevention strategies to those who can benefit most.",
keywords = "Clinical risk factors, Fracture, FRAX{\circledR}, Osteopenia, Osteoporosis",
author = "Siris, {Ethel S.} and Sanford Baim and Aurelia Nattiv",
year = "2010",
month = "1",
day = "1",
doi = "10.3810/pgm.2010.01.2102",
language = "English",
volume = "122",
pages = "82--90",
journal = "Postgraduate Medicine",
issn = "0032-5481",
publisher = "Medquest Communications LLC",
number = "1",

}

TY - JOUR

T1 - Primary care use of FRAX®

T2 - Absolute fracture risk assessment in postmenopausal women and older men

AU - Siris, Ethel S.

AU - Baim, Sanford

AU - Nattiv, Aurelia

PY - 2010/1/1

Y1 - 2010/1/1

N2 - Osteoporosis-related fractures (low-trauma or fragility fractures) cause substantial disability, health care costs, and mortality among postmenopausal women and older men. Epidemiologic studies indicate that at least half the population burden of osteoporosis-related fractures affects persons with osteopenia (low bone density), who comprise a larger segment of the population than those with osteoporosis. The public health burden of fractures will fail to decrease unless the subset of patients with low bone density who are at increased risk for fracture are identified and treated. Risk stratification for medically appropriate and cost-effective treatment is facilitated by the World Health Organization (WHO) FRAX® algorithm, which uses clinical risk factors, bone mineral density, and country-specific fracture and mortality data to quantify a patient's 10-year probability of a hip or major osteoporotic fracture. Included risk factors comprise femoral neck bone mineral density, prior fractures, parental hip fracture history, age, gender, body mass index, ethnicity, smoking, alcohol use, glucocorticoid use, rheumatoid arthritis, and secondary osteoporosis. FRAX® was developed by the WHO to be applicable to both postmenopausal women and men aged 40 to 90 years; the National Osteoporosis Foundation Clinician's Guide focuses on its utility in postmenopausal women and men aged > 50 years. It is validated to be used in untreated patients only. The current National Osteoporosis Foundation Guide recommends treating patients with FRAXR® 10-year risk scores of ≥ 3% for hip fracture or ≥ 20% for major osteoporotic fracture, to reduce their fracture risk. Additional risk factors such as frequent falls, not represented in FRAX®, warrant individual clinical judgment. FRAX® has the potential to demystify fracture risk assessment in primary care for patients with low bone density, directing clinical fracture prevention strategies to those who can benefit most.

AB - Osteoporosis-related fractures (low-trauma or fragility fractures) cause substantial disability, health care costs, and mortality among postmenopausal women and older men. Epidemiologic studies indicate that at least half the population burden of osteoporosis-related fractures affects persons with osteopenia (low bone density), who comprise a larger segment of the population than those with osteoporosis. The public health burden of fractures will fail to decrease unless the subset of patients with low bone density who are at increased risk for fracture are identified and treated. Risk stratification for medically appropriate and cost-effective treatment is facilitated by the World Health Organization (WHO) FRAX® algorithm, which uses clinical risk factors, bone mineral density, and country-specific fracture and mortality data to quantify a patient's 10-year probability of a hip or major osteoporotic fracture. Included risk factors comprise femoral neck bone mineral density, prior fractures, parental hip fracture history, age, gender, body mass index, ethnicity, smoking, alcohol use, glucocorticoid use, rheumatoid arthritis, and secondary osteoporosis. FRAX® was developed by the WHO to be applicable to both postmenopausal women and men aged 40 to 90 years; the National Osteoporosis Foundation Clinician's Guide focuses on its utility in postmenopausal women and men aged > 50 years. It is validated to be used in untreated patients only. The current National Osteoporosis Foundation Guide recommends treating patients with FRAXR® 10-year risk scores of ≥ 3% for hip fracture or ≥ 20% for major osteoporotic fracture, to reduce their fracture risk. Additional risk factors such as frequent falls, not represented in FRAX®, warrant individual clinical judgment. FRAX® has the potential to demystify fracture risk assessment in primary care for patients with low bone density, directing clinical fracture prevention strategies to those who can benefit most.

KW - Clinical risk factors

KW - Fracture

KW - FRAX®

KW - Osteopenia

KW - Osteoporosis

UR - http://www.scopus.com/inward/record.url?scp=76249120071&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=76249120071&partnerID=8YFLogxK

U2 - 10.3810/pgm.2010.01.2102

DO - 10.3810/pgm.2010.01.2102

M3 - Article

C2 - 20107292

AN - SCOPUS:76249120071

VL - 122

SP - 82

EP - 90

JO - Postgraduate Medicine

JF - Postgraduate Medicine

SN - 0032-5481

IS - 1

ER -